Sobi has completed the issuance of Class C shares

STOCKHOLM, August 29, 2024 /PRNewswire/ — The annual general meeting of Swedish Orphan Biovitrum AB (publ) (Sobi^®) on 14 May 2024 resolved to carry out targeted issuances of exchangeable and convertible class C shares and to authorize the Board of Directors to resolve to repurchase all issued class C shares through a takeover bid addressed to all holders of class C shares in Sobi. As previously communicated, the Board of Directors of Sobi resolved on 15 July to repurchase all issued class C shares, subject to subscription and payment by Svenska Handelsbanken AB, in order to secure Sobi’s obligations under the outstanding incentive programs. Svenska Handelsbanken AB has today subscribed for all 1,641,103 issued class C shares and the new share issuances are therefore completed.

The General Meeting of Shareholders of Sobi on May 14, 2024 resolved to carry out targeted issuances of class C shares, with the aim of ensuring that Sobi can meet its obligations under the outstanding long-term incentive programs. Furthermore, the General Meeting resolved to authorize the Board of Directors to resolve to repurchase all issued class C shares through a takeover bid addressed to all owners of class C shares in Sobi.

On 15 July 2024, the Board of Directors of Sobi resolved to repurchase all issued class C shares, subject to subscription and payment by Svenska Handelsbanken AB. Svenska Handelsbanken AB has today subscribed for all 1,641,103 issued class C shares and the new share issues have therefore been completed. The total proceeds of the issues amount to SEK 900,482.19 and have been paid on this day.

Upon the repurchase of all 1,641,103 Class C shares, the intention is to convert the repurchased Class C shares into ordinary shares, in accordance with the conversion provision in Sobi’s articles of association, in order to secure future delivery of ordinary shares to the participants in the outstanding incentive programs.

Sobi currently holds 11,362,970 own common shares and no own class C shares. After the buyback and conversion of the class C shares into common shares, Sobi will hold 13,004,073 own common shares.

Sobi

Sobi^® Sobi, Inc. is a specialized global biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Sobi provides reliable access to innovative medicines in hematology, immunology and specialty care and has approximately 1,800 employees in Europe, North America, the Middle East, Asia and Australia. In 2023, sales amounted to SEK 22.1 billion. Sobi’s share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts
For details on how to contact the Sobi Investor Relations Team, click here. For Sobi Media contacts, click here.
Gerard Tobin
Head of Investor Relations

This information is brought to you by Cision http://news.cision.com.

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-has-completed-issues-of-class-c-shares,c4030712

The following files are available for download:

View original content: https://www.prnewswire.co.uk/news-releases/sobi-has-completed-issues-of-class-c-shares-302234089.html